
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is a company that has demonstrated strong financial discipline and growth potential through its consistent execution of strategic initiatives, including winning manufacturing site transfer agreements and expanding its product offerings. The company has a solid balance sheet, with manageable leverage and a positive outlook for free cash flow generation. Despite recent market setbacks, Lifecore's operational momentum and long-term potential make it a solid investment opportunity for those with a multi-year time horizon.
Bears say
Lifecore Biomedical is showing strong potential for growth with a growing pipeline, which has been estimated to bring in over $100 million in revenue in the late-stage and commercial site transfers category. Despite these promising numbers, the impact on financial results may not be seen until 2028 or 2029. Additionally, the company's recent success in winning three commercial site transfer programs suggests that its efforts to increase visibility and drive capacity utilization are paying off, but the full benefits may not be realized until 2028.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares